JPWO2020159824A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020159824A5 JPWO2020159824A5 JP2021544181A JP2021544181A JPWO2020159824A5 JP WO2020159824 A5 JPWO2020159824 A5 JP WO2020159824A5 JP 2021544181 A JP2021544181 A JP 2021544181A JP 2021544181 A JP2021544181 A JP 2021544181A JP WO2020159824 A5 JPWO2020159824 A5 JP WO2020159824A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- weight
- composition according
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 34
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000009424 thromboembolic effect Effects 0.000 claims description 21
- 239000004067 bulking agent Substances 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 229960002897 heparin Drugs 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 230000003750 conditioning effect Effects 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012736 aqueous medium Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 6
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 210000003709 heart valve Anatomy 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 206010014522 Embolism venous Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 230000001143 conditioned effect Effects 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 150000007518 monoprotic acids Chemical group 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000007519 polyprotic acids Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 2
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 2
- 208000004043 venous thromboembolism Diseases 0.000 claims description 2
- 230000002861 ventricular Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- -1 alkyl cyclodextrin Chemical compound 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 125000004964 sulfoalkyl group Chemical group 0.000 claims 1
- 238000005086 pumping Methods 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798012P | 2019-01-29 | 2019-01-29 | |
| US62/798,012 | 2019-01-29 | ||
| PCT/US2020/015002 WO2020159824A1 (en) | 2019-01-29 | 2020-01-24 | Therapeutic compounds and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523712A JP2022523712A (ja) | 2022-04-26 |
| JP2022523712A5 JP2022523712A5 (https=) | 2023-01-20 |
| JPWO2020159824A5 true JPWO2020159824A5 (https=) | 2023-01-20 |
Family
ID=71841895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544181A Pending JP2022523712A (ja) | 2019-01-29 | 2020-01-24 | 治療用化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210361634A1 (https=) |
| EP (1) | EP3917910A4 (https=) |
| JP (1) | JP2022523712A (https=) |
| KR (1) | KR20210119432A (https=) |
| CN (1) | CN113784951A (https=) |
| AU (1) | AU2020216887A1 (https=) |
| BR (1) | BR112021014956A2 (https=) |
| CA (1) | CA3128018A1 (https=) |
| IL (1) | IL285167A (https=) |
| WO (1) | WO2020159824A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| EP3749662A4 (en) | 2018-02-07 | 2021-07-14 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
| KR20210084581A (ko) * | 2018-10-30 | 2021-07-07 | 엑시테라 파마슈티컬스 인코퍼레이티드 | 치료 화합물 및 조성물 |
| TW202345825A (zh) * | 2022-03-30 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 環狀內醯胺類化合物的注射用藥物組合物及其製備方法 |
| CN117723658A (zh) * | 2023-12-08 | 2024-03-19 | 山东齐都药业有限公司 | Hplc法测定丁苯酞氯化钠注射液中羟丙基倍他环糊精的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| CA2648522A1 (en) * | 2005-04-04 | 2006-10-12 | Daiamed, Inc. | Substituted azetidinones |
| CN103415301A (zh) * | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| RU2733405C2 (ru) * | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| US20190315711A1 (en) * | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2020
- 2020-01-24 EP EP20748002.1A patent/EP3917910A4/en not_active Withdrawn
- 2020-01-24 KR KR1020217025742A patent/KR20210119432A/ko not_active Withdrawn
- 2020-01-24 AU AU2020216887A patent/AU2020216887A1/en not_active Abandoned
- 2020-01-24 CA CA3128018A patent/CA3128018A1/en active Pending
- 2020-01-24 BR BR112021014956-2A patent/BR112021014956A2/pt not_active Application Discontinuation
- 2020-01-24 JP JP2021544181A patent/JP2022523712A/ja active Pending
- 2020-01-24 CN CN202080019754.5A patent/CN113784951A/zh active Pending
- 2020-01-24 WO PCT/US2020/015002 patent/WO2020159824A1/en not_active Ceased
-
2021
- 2021-07-27 IL IL285167A patent/IL285167A/en unknown
- 2021-07-29 US US17/388,859 patent/US20210361634A1/en not_active Abandoned
-
2023
- 2023-04-19 US US18/136,734 patent/US20230270731A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5608038A (en) | Highly concentrated immunoglobulin preparation and method for its production | |
| Dunn et al. | Hemodynamic, metabolic, and hematologic effects of pulsatile cardiopulmonary bypass | |
| KR101130017B1 (ko) | 이코덱스트린을 함유하는 생체친화성 투석액 | |
| US4439181A (en) | Polyol-hormone mixture for use in chronic parenteral hormone administration | |
| JPH09504274A (ja) | 人工表面および血管面の血栓を予防する酸化窒素付加物の利用 | |
| EP1274443B1 (en) | Micelles | |
| Grover et al. | A nonionic surfactant and blood viscosity: experimental observations | |
| JP4638106B2 (ja) | 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用 | |
| Wright et al. | Brain damage and mortality in dogs following pulsatile and non-pulsatile blood flows in extracorporeal circulation | |
| Raijmakers et al. | Transvascular transport of 67Ga in the lungs after cardiopulmonary bypass surgery | |
| Rabe et al. | Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients | |
| JPWO2020159824A5 (https=) | ||
| JP2000038348A (ja) | アルブミン含有腹膜透析液 | |
| HERSCHL et al. | Effects of 5% and 10% guaifenesin infusion on equine vascular endothelium | |
| US11963940B2 (en) | Parenteral esmolol formulation | |
| US20030135196A1 (en) | Treatment of neurologic hemorrhage | |
| RU2021125332A (ru) | Терапевтические соединения и композиции | |
| Luo et al. | Giving priority to lipid administration can reduce lung injury caused by epinephrine in bupivacaine-induced cardiac depression | |
| Yu et al. | Pharmacokinetics of propylene glycol in the rabbit | |
| CN104922060B (zh) | 一种伊班膦酸钠注射液组合物 | |
| JPWO2020092592A5 (https=) | ||
| JP2009522054A (ja) | ヘパリンを含む滅菌済腹膜透析溶液 | |
| JP2003183154A (ja) | ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法 | |
| Demling et al. | Effect of albumin infusion on pulmonary microvascular fluid and protein transport | |
| Kitanishi et al. | Liposomal prostaglandin E1 enhances optic nerve head blood flow in cats |